What is Kyverna Therapeutics, Inc. Common Stock (KYTX) stock price today?

Kyverna Therapeutics, Inc. Common Stock (KYTX) currently trades at $9.47 per share. The stock has a market capitalization of $557.48M and a P/E ratio of —x.

Is KYTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Kyverna Therapeutics, Inc. Common Stock has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is 2.17.

Is Kyverna Therapeutics, Inc. Common Stock financially healthy?

Kyverna Therapeutics, Inc. Common Stock's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of 2.17 places it in the grey zone.

KYTX

Kyverna Therapeutics, Inc. Common Stock

NASDAQ: KYTX · HEALTHCARE · BIOTECHNOLOGY

$9.47

+2.82% today

Updated 2026-05-06

Market cap

$557.48M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.64

Dividend yield

—

52W range

$2 – $14

Volume

0.9M

Market cap

$557.48M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.64

Dividend yield

—

52W range

$2 – $14

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

2.2

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →197 stocks currently score above 75

Price targets

Analyst target

$29.60

+212.57%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Thin margins at 0.00%

- Negative free cash flow $-33.53M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$7.03M	$0.00	$0.00	$0.00	$0.00
Net income	$-28.89M	$-60.37M	$-127.48M	$-161.31M	$-37.80M
EPS	—	—	—	—	$-3.64
Free cash flow	$-36.88M	$-53.03M	$-116.45M	$-153.72M	$-33.53M
Profit margin	-411.29%	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KYTX	$557.48M	28	4.3	3.0	5.0	8.5	—	Avoid
LLY	$862.01B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$546.90B	59	4.7	9.0	3.3	6.0	-40.34%	Buy
ABBV	$365.43B	63	4.0	8.0	4.0	5.0	-22.55%	Buy
UNH	$336.72B	54	5.3	5.5	7.3	4.8	+43.12%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+3.99%	Buy

Smart narrative

Kyverna Therapeutics, Inc. Common Stock trades at $9.47. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.17, it sits in the grey zone.

Frequently asked questions

What is Kyverna Therapeutics, Inc. Common Stock's stock price?

Kyverna Therapeutics, Inc. Common Stock (KYTX) trades at $9.47.

Is Kyverna Therapeutics, Inc. Common Stock overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Kyverna Therapeutics, Inc. Common Stock (KYTX)?

The analyst target price is $29.60, representing +212.6% upside from the current price of $9.47.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

2.17 — grey zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-64.70%

Beta2.06

50D MA$8.76

200D MA$7.06

Shares out0.06B

Float0.04B

Short ratio—

Avg volume0.9M

Performance

1 week-1.33%

1 month+0.00%

3 months+6.48%

YTD-5.64%

1 year—

3 years—

5 years—

Compare

KYTX vs LLY →KYTX vs JNJ →KYTX vs ABBV →Stock screener →